[Present opinions concerning the administration of low molecular weight heparins in hemodialysis patients].
Intradialytic anticoagulation is an essential element of the dialysis procedure. Patients with end stage renal failure, due to the repetitive nature of dialysis sessions are exposed in a chronic manner to side effects of drugs applied during the procedure. Popular administration of unfractionated heparin, concerning its unstable pharmacokinetic profile may cause thrombocytopenia, enhance hyperkalemia, osteoporosis, and lipid disturbances. In the past years, a clinical alternative to unfractionated heparin have become, as well as in dialysis therapy, low molecular weight heparins. Beside the beneficial pharmacokinetic aspect, these heparins are characterized by decreasing number and less intensified side effects associated with their administration.
Drozdz
Maciej
M
Katedra i Klinika Nefrologii, Collegium Medicum, Uniwersytetu Jagiellońskiego w Krakowie. mmdrozdz@cyf-kr.edu.pl
Kowalczyk-Michałek
Martyna
M
Kraśniak
Andrzej
A
Sułowicz
Władysław
W
D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D005343:Fibrinolytic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D006801:Humans; D007676:Kidney Failure, Chronic / Q000188:drug therapy* / Q000628:therapy; D006435:Renal Dialysis
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight